WuXi PharmaTech Breaks Ground on New Cell-Therapy Manufacturing Facility in PhiladelphiaBy
WuXi PharmaTech (Cayman) Inc., a pharmaceutical, biotechnology, and medical device R&D services company with operations in
The new facility will consist of 45,000 square feet of clinical and commercial manufacturing space and will supplement WuXi’s existing 16,000-square-foot cGMP cell-therapy manufacturing facility. The expansion supports increased demand with single-source contract development and cGMP manufacture capabilities for allogeneic and autologous cell-based therapeutics.The new facility will be built using modular design, flexible cleanroom technology, disposable equipment, and microcarrier cell-culture systems.
Located in the Philadelphia Navy Yard, the new facility will complement WuXi’s existing facility and capabilities, which include analytical chemistry, cell banking, cell characterization, molecular biology, and lot-release testing, thereby providing integrated services for cell therapies in
Source: Wuxi PharmaTech